This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-28 and is reviewed periodically as new material appears.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved for therapeutic use | No marketing authorisation from major agencies |
| Legal classification | Varies by jurisdiction | Prescription-only or controlled in several countries |
| Common synonyms | Melanotan II; MT-II | Also referenced by catalogue codes |
| Typical analytical method | Reverse-phase HPLC | Often paired with mass spectrometry |
| Primary literature focus | Receptor pharmacology | Pigmentation and melanocortin signalling |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
There is currently no use for any isotope of berkelium outside basic scientific research. Berkelium-249 is a common target nuclide to prepare still heavier transuranium elements and superheavy elements, such as lawrencium, rutherfordium and bohrium. It is also useful as a source of the isotope californium-249, which is used for studies on the chemistry of californium in preference to the more radioactive californium-252 that is produced in neutron bombardment facilities such as the HFIR. A 22 milligram batch of berkelium-249 was prepared in a 250-day irradiation and then purified for 90 days at Oak Ridge in 2009. This target yielded the first 6 atoms of tennessine at the Joint Institute for Nuclear Research (JINR), Dubna, Russia, after bombarding it with calcium ions in the U400 cyclotron for 150 days. This synthesis was a culmination of the Russia-US collaboration between JINR and Lawrence Livermore National Laboratory on the synthesis of elements 113 to 118 which was initiated in 1989.
== Collaboration == Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed its company name to Oncothyreon Inc. in 2007. Oncothyreon is now located in Seattle, Washington, and it changed its name to SGEN after a merger and acquisition in March 2018. In 2001, Merck KGaA, of Darmstadt, Germany, entered into a collaboration and supply agreement with Biomira. In 2007, Merck KGaA acquired the exclusive worldwide marketing rights from Biomira, and Merck KGaA has since then been entirely responsible for the further clinical development of tecemotide. In 2008, Merck KGaA acquired the manufacturing rights for tecemotide from Oncothyreon. In 2011, Ono Pharmaceutical Company, of Japan, acquired a co-development and co-marketing license for tecemotide in Japan; Ono paid Merck KGaA 5 million euros.
In organic chemistry, secondary amino acids are amino acids which do not contain the amino group −NH2 but are rather a secondary amine (>NH). Secondary amino acids can be classified to cyclic acids, such as proline, and acyclic N-substituted amino acids. In nature, proline, hydroxyproline, pipecolic acid and sarcosine are well-known secondary amino acids. Proline is the only proteinogenic secondary amino acid; all other secondary amino acids are non-proteinogenic. Hydroxyproline is incorporated into proteins by hydroxylation of proline. Pipecolic acid, a heavier analog of proline, is found in efrapeptin. Sarcosine is a N-methylated glycine in which the methyl group is used in many biochemical reactions. Azetidine-2-carboxylic acid is a smaller homolog of proline that is found in plants.
Sources: en.wikipedia.org
Researchers have found ways for pregnant women with gestational diabetes to reduce their complications with their current health, long-term effects, and fetal health with the help of exercise. Laredo-Aguilera, et al., and Dipla, et al., presented findings from systematic and meta-analyses that showed positive effects of resistance exercise or a combination of resistance and aerobic exercise. Aerobic and resistance training were found to control glucose, HgbA1c, and insulin levels in women with GDM. Not only is the mother's health affected, but also the fetus's. If GDM is not treated or is made worse, the child may suffer from macrosomia, impaired intrauterine growth, obstetric trauma, hyperbilirubinemia, hypoglycemia, or even infection. Pregnant women with GDM who are overweight or obese are at a greater risk of passing down these negative effects by 2.14-3.56 times. Benefits to resistance and aerobic exercise include a maternal decrease in cramps, lower back pain, edema, depression, urinary incontinence, duration of labor, constipation, and the number of c-sections. These benefits can affect the fetus by having a decreased body fat mass, improved stress tolerance, and advanced neurobehavioral maturation. In the article written by Laredo-Aguilera, et al., there were seven interventions and seven different countries that were used for research. Within all of the interventions, there were significant improvements in glucose concentration, reduced requirements of insulin injections, postprandial glucose level control, and glycemic control.
Copper-64 (64Cu) is a positron- and beta-emitting isotope of copper (exhibiting both forms of beta decay), with applications in molecular radiotherapy and positron emission tomography. Its unusually long half-life (12.7 hours) for a positron-emitting isotope makes it increasingly useful when attached to various ligands for PET and PET-CT scanning.
Humanitarian agencies in Yemen operate in an environment shaped by military, administrative and political constraints imposed by the different sides of the conflict. At sea, naval controls, inspection regimes and port restrictions have delayed or limited the arrival of food, fuel and medical supplies, creating recurrent logistical challenges. In territories controlled by the Houthis instead, aid efforts have also been victim of a dense bureaucracy, as the creation of the Supreme Council for the Management and Coordination of Humanitarian Affairs (SCMCHA) gave the Houthis decisional power over project approvals, staff movement, and local partnerships among many other things. Reports from donors and humanitarian organizations describe then diversion of assistance, pressure to channel funds and contracts through Houthi-linked entities, black-market resale of aid and attempts to impose additional taxes on humanitarian programmes, all of which have delayed operations and increased their cost. Donor governments have debated imposing stricter conditions or suspending some forms of assistance in response to these actions, but such measures have been pursued cautiously because of concerns that a reduction in aid would primarily affect civilians who depend on it.
== Early life and career == Reid, who originally played football for the North Balwyn Methodists, played two senior games for Hawthorn in the 1966 VFL season and one further game the following year. Reid was a member of Preston's 1968 and 1969 Victorian Football Association premiership teams. Having graduated from university with a medical degree while at Preston, Reid worked as a club doctor with Richmond from 1976 to 1979.
Sources: en.wikipedia.org
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.
Much of the evidence comes from case reports and accounts of unregulated use rather than controlled trials. Differences in product purity and dosing add further variability.
Laboratory work focuses on receptor binding and cellular signalling. Observational reports document outcomes after use, and analytical chemists examine samples to assess content and purity.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.